Davis's Drug Guide
Glyxambi 10/5
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Glyxambi 10/5." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110215/all/Glyxambi_10_5.
Vallerand AHA, Sanoski CAC, Quiring CC. Glyxambi 10/5. Davis's Drug Guide. F.A. Davis Company; 2024. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110215/all/Glyxambi_10_5. Accessed November 12, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Glyxambi 10/5. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110215/all/Glyxambi_10_5
Vallerand AHA, Sanoski CAC, Quiring CC. Glyxambi 10/5 [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 November 12]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110215/all/Glyxambi_10_5.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Glyxambi 10/5
ID - 110215
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110215/all/Glyxambi_10_5
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
